FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2979331688> ?p ?o ?g. }

• W2979331688 abstract "Abstract Abstract 2087 Poster Board II-64 Acute myeloid leukemia (AML) most frequently affects the elderly, many of whom are unable to tolerate intensive chemotherapy. Therefore, improvements in clinical outcomes for patients with AML largely depend upon the development of novel targeted therapies. Aurora A is a serine/threonine kinase that plays a key role in mitosis by regulating the G2-M transition, centrosome separation, spindle assembly and chromosome segregation. It is overexpressed in AML and has been implicated in genetic instability, disease progression and drug resistance. MLN8237 is a novel orally available Aurora A inhibitor that has entered Phase I and Phase II trials for cancer therapy. Based on the critical role of Aurora A in cell cycle regulation and its intrinsic overexpression in AML cells, we hypothesized that MLN8237 would possess significant antileukemic activity. We tested our hypothesis in established human AML cell lines, primary AML patient specimens, and a mouse model of AML. MLN8237 potently inhibited the in vitro growth and survival of all AML cell lines and primary human AML cells from patients with newly diagnosed AML and patients with relapsed, chemotherapy resistant disease. Mechanistic studies showed that MLN8237 reduced the activity of Aurora A kinase as evidenced by reduced phosphorylation of Aurora A at Thr288. MLN8237 treatment also disrupted normal cell cycle kinetics and induced apoptosis in a dose- and time-dependant manner characterized by the accumulation of G2/M and aneuploid cells prior to the onset of apoptosis. Exposure to MLN8237 led to activation of FOXO3a followed by a dose-dependent increase in the expression of its transcriptional target Bim. These events appear to be important mediators of the pro-apoptotic effects of this agent. We next investigated the ability of MLN8237 to increase the efficacy of cytarabine in AML. Treatment with the combination of MLN8237 and cytarabine resulted in significantly greater apoptosis and more effective inhibition of survival than treatment with either agent alone in AML cell lines and primary patient specimens. MLN8237 and cytarabine cooperated to enhance mitochondrial-mediated apoptosis as evidenced by increased processing of caspases-9 and -3 to active forms. Daily oral administration of MLN8237 to immunodeficient mice bearing AML xenografts was well tolerated, effectively reduced tumor growth and led to the disruption of mitotic spindles and centrosome amplification. Moreover, MLN8237 significantly enhanced the activity of cytarabine to achieve tumor regression. Our data demonstrates that MLN8237 has a multifaceted mechanism of action comprised of pro-apoptotic and growth inhibitory effects. Our collective findings indicate that the combination of MLN8237 and cytarabine represents a novel, very promising therapeutic strategy for AML. A clinical study investigating the safety and efficacy of this combination in patients with refractory AML is planned. Disclosures: Ecsedy: Millennium Pharmaceuticals: Employment." @default.
• W2979331688 created "2019-10-18" @default.
• W2979331688 creator A5004814161 @default.
• W2979331688 creator A5005922094 @default.
• W2979331688 creator A5007822188 @default.
• W2979331688 creator A5018391856 @default.
• W2979331688 creator A5032988049 @default.
• W2979331688 creator A5038292671 @default.
• W2979331688 creator A5053953098 @default.
• W2979331688 creator A5057890851 @default.
• W2979331688 creator A5061285204 @default.
• W2979331688 creator A5062792047 @default.
• W2979331688 creator A5076001431 @default.
• W2979331688 date "2009-11-20" @default.
• W2979331688 modified "2023-10-10" @default.
• W2979331688 title "The Novel Orally Active Aurora A Kinase Inhibitor MLN8237 Is Highly Active in Preclinical Models of Acute Myeloid Leukemia and Significantly Increases the Efficacy of Cytarabine." @default.
• W2979331688 doi "https://doi.org/10.1182/blood.v114.22.2087.2087" @default.
• W2979331688 hasPublicationYear "2009" @default.
• W2979331688 type Work @default.
• W2979331688 sameAs 2979331688 @default.
• W2979331688 citedByCount "1" @default.
• W2979331688 countsByYear W29793316882016 @default.
• W2979331688 crossrefType "journal-article" @default.
• W2979331688 hasAuthorship W2979331688A5004814161 @default.
• W2979331688 hasAuthorship W2979331688A5005922094 @default.
• W2979331688 hasAuthorship W2979331688A5007822188 @default.
• W2979331688 hasAuthorship W2979331688A5018391856 @default.
• W2979331688 hasAuthorship W2979331688A5032988049 @default.
• W2979331688 hasAuthorship W2979331688A5038292671 @default.
• W2979331688 hasAuthorship W2979331688A5053953098 @default.
• W2979331688 hasAuthorship W2979331688A5057890851 @default.
• W2979331688 hasAuthorship W2979331688A5061285204 @default.
• W2979331688 hasAuthorship W2979331688A5062792047 @default.
• W2979331688 hasAuthorship W2979331688A5076001431 @default.
• W2979331688 hasConcept C121608353 @default.
• W2979331688 hasConcept C126322002 @default.
• W2979331688 hasConcept C203014093 @default.
• W2979331688 hasConcept C20552341 @default.
• W2979331688 hasConcept C2778041864 @default.
• W2979331688 hasConcept C2778461978 @default.
• W2979331688 hasConcept C2778729363 @default.
• W2979331688 hasConcept C2779425043 @default.
• W2979331688 hasConcept C29537977 @default.
• W2979331688 hasConcept C502942594 @default.
• W2979331688 hasConcept C71924100 @default.
• W2979331688 hasConcept C86803240 @default.
• W2979331688 hasConceptScore W2979331688C121608353 @default.
• W2979331688 hasConceptScore W2979331688C126322002 @default.
• W2979331688 hasConceptScore W2979331688C203014093 @default.
• W2979331688 hasConceptScore W2979331688C20552341 @default.
• W2979331688 hasConceptScore W2979331688C2778041864 @default.
• W2979331688 hasConceptScore W2979331688C2778461978 @default.
• W2979331688 hasConceptScore W2979331688C2778729363 @default.
• W2979331688 hasConceptScore W2979331688C2779425043 @default.
• W2979331688 hasConceptScore W2979331688C29537977 @default.
• W2979331688 hasConceptScore W2979331688C502942594 @default.
• W2979331688 hasConceptScore W2979331688C71924100 @default.
• W2979331688 hasConceptScore W2979331688C86803240 @default.
• W2979331688 hasLocation W29793316881 @default.
• W2979331688 hasOpenAccess W2979331688 @default.
• W2979331688 hasPrimaryLocation W29793316881 @default.
• W2979331688 hasRelatedWork W1449405988 @default.
• W2979331688 hasRelatedWork W1965478253 @default.
• W2979331688 hasRelatedWork W1967387100 @default.
• W2979331688 hasRelatedWork W1985076650 @default.
• W2979331688 hasRelatedWork W2019142623 @default.
• W2979331688 hasRelatedWork W2558250642 @default.
• W2979331688 hasRelatedWork W2562652923 @default.
• W2979331688 hasRelatedWork W2575464554 @default.
• W2979331688 hasRelatedWork W2576588127 @default.
• W2979331688 hasRelatedWork W2581374904 @default.
• W2979331688 hasRelatedWork W2588517367 @default.
• W2979331688 hasRelatedWork W2766507491 @default.
• W2979331688 hasRelatedWork W2916665060 @default.
• W2979331688 hasRelatedWork W2952486531 @default.
• W2979331688 hasRelatedWork W2979933918 @default.
• W2979331688 hasRelatedWork W2980119394 @default.
• W2979331688 hasRelatedWork W2980245895 @default.
• W2979331688 hasRelatedWork W3093238909 @default.
• W2979331688 hasRelatedWork W3186606314 @default.
• W2979331688 hasRelatedWork W3193934226 @default.
• W2979331688 isParatext "false" @default.
• W2979331688 isRetracted "false" @default.
• W2979331688 magId "2979331688" @default.
• W2979331688 workType "article" @default.